These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

348 related items for PubMed ID: 31916060

  • 1. Investigation of genetic base in the treatment of age-related macular degeneration.
    Gourgouli K, Gourgouli I, Tsaousis G, Spai S, Niskopoulou M, Efthimiopoulos S, Lamnissou K.
    Int Ophthalmol; 2020 Apr; 40(4):985-997. PubMed ID: 31916060
    [Abstract] [Full Text] [Related]

  • 2. Association of Single-Nucleotide Polymorphisms in Age-Related Macular Degeneration With Pseudodrusen: Secondary Analysis of Data From the Comparison of AMD Treatments Trials.
    Lin LY, Zhou Q, Hagstrom S, Maguire MG, Daniel E, Grunwald JE, Martin DF, Ying GS, CATT Research Group.
    JAMA Ophthalmol; 2018 Jun 01; 136(6):682-688. PubMed ID: 29801032
    [Abstract] [Full Text] [Related]

  • 3. Genetic influences on the outcome of anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration.
    Abedi F, Wickremasinghe S, Richardson AJ, Islam AF, Guymer RH, Baird PN.
    Ophthalmology; 2013 Aug 01; 120(8):1641-8. PubMed ID: 23582991
    [Abstract] [Full Text] [Related]

  • 4. Single-Nucleotide Polymorphisms Associated With Age-Related Macular Degeneration and Lesion Phenotypes in the Comparison of Age-Related Macular Degeneration Treatments Trials.
    Maguire MG, Ying GS, Jaffe GJ, Toth CA, Daniel E, Grunwald J, Martin DF, Hagstrom SA, CATT Research Group.
    JAMA Ophthalmol; 2016 Jun 01; 134(6):674-81. PubMed ID: 27099955
    [Abstract] [Full Text] [Related]

  • 5. Cumulative effect of risk alleles in CFH, ARMS2, and VEGFA on the response to ranibizumab treatment in age-related macular degeneration.
    Smailhodzic D, Muether PS, Chen J, Kwestro A, Zhang AY, Omar A, Van de Ven JP, Keunen JE, Kirchhof B, Hoyng CB, Klevering BJ, Koenekoop RK, Fauser S, den Hollander AI.
    Ophthalmology; 2012 Nov 01; 119(11):2304-11. PubMed ID: 22840423
    [Abstract] [Full Text] [Related]

  • 6. Association between CFH, CFB, ARMS2, SERPINF1, VEGFR1 and VEGF polymorphisms and anatomical and functional response to ranibizumab treatment in neovascular age-related macular degeneration.
    Cobos E, Recalde S, Anter J, Hernandez-Sanchez M, Barreales C, Olavarrieta L, Valverde A, Suarez-Figueroa M, Cruz F, Abraldes M, Pérez-Pérez J, Fernández-Robredo P, Arias L, García-Layana A.
    Acta Ophthalmol; 2018 Mar 01; 96(2):e201-e212. PubMed ID: 28926193
    [Abstract] [Full Text] [Related]

  • 7. ARMS2 A69S polymorphism is associated with the number of ranibizumab injections needed for exudative age-related macular degeneration in a pro re nata regimen during 4 years of follow-up.
    Valverde-Megías A, Veganzones-de-Castro S, Donate-López J, Maestro-de-Las-Casas ML, Megías-Fresno A, García-Feijoo J.
    Graefes Arch Clin Exp Ophthalmol; 2017 Nov 01; 255(11):2091-2098. PubMed ID: 28744656
    [Abstract] [Full Text] [Related]

  • 8. Effects of aflibercept for ranibizumab-resistant neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.
    Kawashima Y, Oishi A, Tsujikawa A, Yamashiro K, Miyake M, Ueda-Arakawa N, Yoshikawa M, Takahashi A, Yoshimura N.
    Graefes Arch Clin Exp Ophthalmol; 2015 Sep 01; 253(9):1471-7. PubMed ID: 25391986
    [Abstract] [Full Text] [Related]

  • 9. Complement factor H Y402H gene polymorphism and response to intravitreal bevacizumab in exudative age-related macular degeneration.
    Nischler C, Oberkofler H, Ortner C, Paikl D, Riha W, Lang N, Patsch W, Egger SF.
    Acta Ophthalmol; 2011 Jun 01; 89(4):e344-9. PubMed ID: 21232084
    [Abstract] [Full Text] [Related]

  • 10. GENETICS OF LARGE PIGMENT EPITHELIAL DETACHMENTS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
    Mouallem-Beziere A, Blanco-Garavito R, Richard F, Miere A, Jung C, Rozet JM, Souied EH.
    Retina; 2020 Apr 01; 40(4):663-671. PubMed ID: 30681643
    [Abstract] [Full Text] [Related]

  • 11. Genetic Variants of Complement Factor H Y402H (rs1061170), C2 R102G (rs2230199), and C3 E318D (rs9332739) and Response to Intravitreal Anti-VEGF Treatment in Patients with Exudative Age-Related Macular Degeneration.
    Kubicka-Trząska A, Żuber-Łaskawiec K, Dziedzina S, Sanak M, Romanowska-Dixon B, Karska-Basta I.
    Medicina (Kaunas); 2022 May 13; 58(5):. PubMed ID: 35630075
    [Abstract] [Full Text] [Related]

  • 12. Comparison of ARMS2/LOC387715 A69S and CFH Y402H risk effect in wet-type age-related macular degeneration: a meta-analysis.
    Jabbarpoor Bonyadi MH, Yaseri M, Nikkhah H, Bonyadi M, Nazari R, Soheilian M.
    Int Ophthalmol; 2019 Apr 13; 39(4):949-956. PubMed ID: 29423786
    [Abstract] [Full Text] [Related]

  • 13. [Association between Y402H, E318D and R102G polymorphisms of complement proteins genes and the response to intravitreal anti-VEGF treatment in patients with neovascular age-related macular degeneration].
    Kubicka-Trząska A, Karska-Basta I, Kobylarz J, Dziedzina S, Sanak M, Romanowska-Dixon B.
    Klin Oczna; 2016 Apr 13; 118(2):114-21. PubMed ID: 29912491
    [Abstract] [Full Text] [Related]

  • 14. Association of the CFH Y402H Polymorphism with the 1-Year Response of Exudative AMD to Intravitreal Anti-VEGF Treatment in the Brazilian Population.
    Medina FMC, Motta AALD, Takahashi WY, Carricondo PC, Motta MMDS, Melo MB, Vasconcellos JPC.
    Ophthalmic Res; 2019 Apr 13; 61(3):168-173. PubMed ID: 28641277
    [Abstract] [Full Text] [Related]

  • 15. Factors associated with the response of age-related macular degeneration to intravitreal ranibizumab treatment.
    Yamashiro K, Tomita K, Tsujikawa A, Nakata I, Akagi-Kurashige Y, Miyake M, Ooto S, Tamura H, Yoshimura N.
    Am J Ophthalmol; 2012 Jul 13; 154(1):125-36. PubMed ID: 22465368
    [Abstract] [Full Text] [Related]

  • 16. Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT).
    Hagstrom SA, Ying GS, Pauer GJT, Sturgill-Short GM, Huang J, Callanan DG, Kim IK, Klein ML, Maguire MG, Martin DF, Comparison of AMD Treatments Trials Research Group.
    Ophthalmology; 2013 Mar 13; 120(3):593-599. PubMed ID: 23337555
    [Abstract] [Full Text] [Related]

  • 17. Genetic Variants Affecting Anti-VEGF Drug Response in Polypoidal Choroidal Vasculopathy Patients: A Systematic Review and Meta-Analysis.
    Díaz-Villamarín X, Blánquez-Martínez D, Pozo-Agundo A, Pérez-Gutiérrez AM, Muñoz-Ávila JI, Antúnez-Rodríguez A, Fernández-Gómez AE, García-Navas P, Martínez-González LJ, Dávila-Fajardo CL.
    Genes (Basel); 2020 Nov 12; 11(11):. PubMed ID: 33198211
    [Abstract] [Full Text] [Related]

  • 18. Association of Smoking and CFH and ARMS2 Risk Variants With Younger Age at Onset of Neovascular Age-Related Macular Degeneration.
    Lechanteur YT, van de Camp PL, Smailhodzic D, van de Ven JP, Buitendijk GH, Klaver CC, Groenewoud JM, den Hollander AI, Hoyng CB, Klevering BJ.
    JAMA Ophthalmol; 2015 May 12; 133(5):533-41. PubMed ID: 25695752
    [Abstract] [Full Text] [Related]

  • 19. Role of complement factor B rs4151667 (L9H) polymorphisms and its interactional role with CFH Y402H and C3 rs2230199 (R102G) risk variants in age-related macular degeneration: a case control study.
    Roshanipour N, Laleh MG, Bonyadi M, Bonyadi MHJ, Soheilian M, Javadzadeh A, Yaseri M.
    BMC Ophthalmol; 2020 Aug 06; 20(1):323. PubMed ID: 32762675
    [Abstract] [Full Text] [Related]

  • 20. CFH Y402H and VEGF Polymorphisms and Anti-VEGF Treatment Response in Exudative Age-Related Macular Degeneration.
    Kepez Yildiz B, Ozdek S, Ergun MA, Ergun S, Yaylacioglu Tuncay F, Elbeg S.
    Ophthalmic Res; 2016 Aug 06; 56(3):132-8. PubMed ID: 27404493
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.